The Future of IV Platelet Inhibition in the Catheterization Laboratory-Cangrelor - The Data Behind When and Why to Use IV Anti-Platelet Therapy in the Catheterization Laboratory, Dr. Jennifer A. Rymer

Cangrelor - The Data Behind When and Why to Use IV Anti-Platelet Therapy in the Catheterization Laboratory, Dr. Jennifer A. Rymer

Back to course

Video Transcription

Video Summary

The talk focuses on Cangrelor, an IV antiplatelet, discussing its usage in various clinical situations, including cardiogenic shock, patient scenarios with inadequate oral antiplatelet loading, and complex PCI procedures. The Champion Phoenix trial demonstrated Cangrelor's effectiveness, showing lower rates of major adverse cardiac events and stent thrombosis compared to clopidogrel. Real-world registry data supports its use, highlighting advantages like quick onset and offset, especially in scenarios where patients have absorption issues or are intubated. Considerations must factor into patient management, where IV antiplatelet agents provide adequate and rapid platelet inhibition.

Keywords

Cangrelor

antiplatelet

cardiogenic shock

Champion Phoenix trial

stent thrombosis